Global Contrast Media/Contrast Agent Market Forecast to 2026 - Asia is Expected to Offer Strong Growth Opportunities - ResearchAndMarkets.com

·4 min read

DUBLIN, July 28, 2021--(BUSINESS WIRE)--The "Global Contrast Media/Contrast Agent Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global contrast media/contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.

The growth in this market can be attributed to the rising prevalence of chronic diseases, growing approvals of contrast agents, rising volume of CT and MRI examinations performed, growing number of diagnostic centers and hospitals, and availability of reimbursement.

Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, high cost and inaccessibility of advanced therapeutics may restrict market growth to a certain extent. The contrast media/contrast agents market is segmented based on type, modality, route of administration, indication, application, end user, and region.

Iodinated contrast media segment is expected to dominate the market during the forecast period

Based on type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media. Iodinated contrast media account for the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.

X-ray/CT segment to dominate the market during the forecast period

Based on modality, contrast media/contrast agents can be segmented into X-ray/CT, MRI and Ultrasound. X-ray/CT accounts for the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the increasing number of CT examinations across the globe, coupled with advancements in CT imaging technologies that majorly use injectable contrast media.

Intravascular route segment holds highest market share during the forecast period and is also expected to grow at the highest CAGR during the forecast period

Based on routes of administration, the contrast media/contrast agents market is segmented into oral, intravascular, rectal, and other routes of administration. The intravascular route segment is expected to hold the majority of the market share and have the highest growth rate. The widespread use of injectable contrast media in most modern imaging modalities, such as CT and MRI scanning, is one of the major factors driving the growth of the intravascular segment.

Cardiovascular disorders segment holds highest market share during the forecast period and is also expected to grow at the highest CAGR during the forecast period

Based on indication, the contrast media/contrast agents market has been segmented into cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. Cardiovascular disorders accounted for the largest market share and highest growth rate. The large share of this segment can be attributed to the rising geriatric population and the increasing prevalence of CVD across the globe.

Radiology segment to dominate the market during the forecast period

Based on application, the contrast media/contrast agents market is segmented into radiology, interventional radiology, and interventional cardiology. The radiology applications segment commanded the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the increasing use of medical imaging techniques, such as X-ray, CT, MRI, and ultrasound, in these applications.

Hospitals, Clinics & Ambulatory Surgery Centers segment to dominate the market during the forecast period

Based on end user, the contrast media/contrast agents market is segmented into hospitals, clinics, and ASCs and diagnostic imaging centers. Hospitals, clinics, and ASCs for the largest share of the contrast media/contrast agents market. The large share is attributed to the rising number of hospitals across the globe.

North America will dominate the market during the forecast period

The global contrast media/contrast agents market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of Asia Pacific), Latin America and Middle East & Africa. In 2020, North America dominated the global contrast media/contrast agents market, followed by Europe. The large share of the North American market can be attributed to the presence of major players in the region, high prevalence of chronic disorders, growing geriatric population, and the increasing adoption of minimally invasive procedures.

List of Companies Profiled in the Report

  • GE Healthcare (US)

  • Bracco Imaging SPA (Italy)

  • Bayer AG (Germany)

  • Guerbet (France)

  • Lantheus Medical Imaging, Inc. (US)

  • Unijules Life Sciences (India)

  • J.B. Chemicals and Pharmaceuticals Ltd. (India)

  • SANOCHEMIA Pharmazeutika GmbH (Austria)

  • Taejoon Pharm (South Korea)

  • JodasExpoim (India)

  • Nano Therapeutics Pvt. Ltd. (India)

  • Kiran X-ray (India)

  • iMax Diagnostic Imaging Limited (Ireland)

  • YZJ Group (China)

  • Livealth Biopharma Pvt. Ltd. (India)

  • Trivitron Healthcare Pvt. Ltd. (India)

  • Novalek Pharmaceuticals Pvt. Ltd. (India)

  • Unispire Biopharma Private Limited (India)

  • Acro Lifesciences (I) Pvt. Ltd. (India)

  • Congruent Pharmachem Private Limited (India)

  • Stanex Drugs & Chemical Pvt. Ltd. (India)

  • Beijing Beilu Pharmaceutical Co., Ltd. (China)

  • Rege Imaging & Cine Films Private Limited (India)

  • K DIAM EXIM (India)

  • Onko Ilac San. ve Tic. A.S. (Turkey)

  • Subhra Pharma Pvt. Ltd. (India)

For more information about this report visit https://www.researchandmarkets.com/r/7ejjx

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005582/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting